UCL ADVANCED CENTRE FOR
Biochemical Engineering
In this issue
IMRC for Bioprocessing Phase 3
IChemE
ChemE Accreditation:
Skilled Biochemical Engineers
Vision 2011: Senior Leadership Course
EPSRC Centre for Innovative
Manufacturing in Emergent
Macromolecular Therapies
Responsive Bioprocessing Facility
Completion
Bioprocess Briefings
SME Engagement: Immbio
ISSUE SEVEN | AUGUST 2011
Contents
Editorial
Editorial
2
Foreword by Professor Nigel Titchener-Hooker
Departmental news
3
Skilled Biochemical
Engineers
6
Vision 2011 Senior
Leadership Course
8
Welcome to this seventh edition of BioProcessing Matters.
Against a backdrop of radical changes to funding of
undergraduate students it is good to be able to report that
UCL Biochemical Engineering continues to develop its
portfolio of programmes and to demonstrate the quality and
relevance of these. Furthermore, as funds for research become
yet more focused it is important that we continue to win
support for our research vision and initiatives in knowledge
exchange.
This particular issue of BioProcessing Matters provides a snapshot of departmental
activities and plans over the past months. Many of the outcomes are a result of years of
careful planning and represent the culmination of significant team efforts. This is very
much our ethos – to be a team focused on creating the individuals skilled in the very
latest advances and methods needed for this key industry. These are big challenges but
as you read through the following examples I believe it is clear that UCL Biochemical
Engineering is rising to each of them.
EPSRC Centre for
Innovative Manufacturing
in Emergent
Macromolecular Therapies 11
Responsive Bioprocessing
Facility – Planning for
the Future
12
Bioprocess Briefings
13
SME Engagement:
Immbio Case Study
14
MBI® Module: Principles
of Fermentation
(3–5 October 2011)
15
MBI® course dates 2011–12 16
Prof. Nigel Titchener-Hooker
Head of Department and Director of the Advanced Centre for
Biochemical Engineering
2
Departmental news
Providing access to our research outputs through
refereed publications
Our publications list 2006–2010 is available in hard
copy and highlights our ‘best picks’. Additionally, we
have a more extensive list of 2002–2010 publications
available as a Word document with embedded
hyperlinks to the online publications. If you would
like to receive a copy of either, please contact
Dr Karen Smith (karen.smith@ucl.ac.uk).
IMRC for Bioprocessing Phase 3
A key output of the EPSRC Innovative
Manufacturing Research Centre (IMRC)
for Bioprocessing has been the discovery and
development of ultra-scale-down devices and
methods designed to provide new insights and
solutions of the challenges for processing of next
generation biological materials. Examples of such ultra scale-down methods are
shown on page 7 and on page 14..
All stages from fermentation and cell culture to primary recovery to purification
to formulation and finishing have been addressed within the IMRC. This has been
a result of ten years’ collaboration with industrial experts (over 40 companies have
been involved) and academic experts within and outside UCL.
The main UCL players in this activity have been:
• Dr Frank Baganz (fermentation and cell culture)
• Dr Dan Bracewell (primary recovery and chromatography)
• Dr Paul Dalby (protein engineering and formulation)
• Dr Suzy Farid (decision-support tools)
• Prof. Eli Keshavarz-Moore (cell bioprocessing)
• Prof. Mike Hoare (whole bioprocess ultra scale-down and primary recovery)
• Prof. Gary Lye (microbiochemical engineering and industrial biotechnology)
• Prof. Chris Mason (regenerative medicine bioprocessing)
• Dr Martina Micheletti (cell culture microwell engineering)
• Dr Tarit Mukhopadhyay (vaccine bioprocessing )
• Dr Darren Nesbeth (synthetic biology bioprocessing)
• Dr Karen Smith (knowledge transfer)
• Prof. Nigel Titchener-Hooker (whole bioprocess analysis)
• Dr Ivan Wall (regenerative medicines bioprocessing)
• Prof. John Ward (cell engineering)
• Dr Yuhong Zhou (bioprocessing data acquisition)
3
We are now entering the third phase of the IMRC. This is focused on establishing the use of ultra-scale-down
technologies in the bioprocessing industries, not only for biopharmaceuticals but also vaccines, stem cell therapies and
products of industrial biotechnology.
We would like to express our thanks to the EPSRC and to our industrial collaborators for their support and to
Management Committee Members (Chair Prof. John Mann) and the Steering Group (Chair Richard Francis) for
giving their time and invaluable insights..
Hard copies of our 2011 Report are now available to IMRC member companies. A downloadable pdf version is also
available via our IMRC web portal at www.ucl.ac.uk/biochemeng/industry/imrc.
For more information about IMRC Phase 3, please contact Prof Mike Hoare at m.hoare@ucl.ac.uk.
Industrial Training Open Day Success
We held our annual Industrial Training Day on 14 March and, as usual, attracted a superb range of attendees from
industry. Representatives from a wide range of companies such as BP, GSK, MedImmune, Pfizer and UCB enjoyed
hearing about our latest training initiatives at undergraduate, postgraduate and post-experience levels and had an
opportunity to meet our students at a well-received Poster Session in the afternoon. The BPL-sponsored Poster Prize
this year went to Kane Miller for his poster entitled Design and Evaluation of an Internally Radiating Photobioreactor for
Generic Application of Algal-Based Production Systems.
Suzy Farid FIChemE
Congratulations to Dr Suzy Farid
(pictured, right) on becoming a
Fellow of the Institution of Chemical
Engineers. In order to become a
Fellow one must be an engineering
professional of distinction, making
a significant contribution to one’s
profession – an excellent description
of Suzy. There is also a requirement
to show technical excellence and
leadership of peers which Suzy has
repeatedly demonstrated.
Clive Osborn Retires
After an incredible 40 years with the
Department, we say goodbye to Clive
Osborn, our Facilities Manager, who
retired this Spring. Clive saw the
department grow from the cramped
conditions within a retrofitted pilot
plant (where he worked as a technician
4
on a research grant) to the purpose-designed facilities of the ACBE which he very
ably managed with his team of technical experts. Generations of student researchers
as well as numerous academic staff benefited from Clive’s professionalism and
his huge knowledge of bioprocessing. Most crucially Clive developed an intimate
knowledge of all the support infrastructure necessary for the effective functioning of
a state-of-the-art facility. Cheerful even when faced with apparent calamities such as
collapsed ceilings due to ruptured water pipes, Clive was ingenious in securing the
best possible help from central College support. Clive helped to realise the research
and training goals that now characterise the department. We are not quite sure what
Clive has planned but we wish him the very best of good fortune in his retirement.
Gareth Mannell takes over the role.
IChemE Bursary
We are delighted that one of our third year students, Asma Ahmad, has won an
IChemE Pharma Group summer research bursary. She will work with PhD student
Ebenezer Ojo and Prof. Gary Lye on ‘Parallel Evaluation of Algae for Sustainable
Production of Biopharmaceuticals Using Miniature Photobioreactors’ .
The project aims to explore recombinant protein production in algae. Algae
represent a relatively unexplored alternative to current microbial and mammalian
expression systems. Potentially they offer a number of significant advantages including
cheaper manufacture (simple defined media), sustainable and environmentally
friendly processes and increased safety (lack of contamination with human viruses).
This bursary will give Asma the opportunity of an extended period of handson experimentation and experience of independent experimental design. It will
also provide her with valuable laboratory skills in analysis and cell culture (these
complement the pilot plant processing skills she has already gained during her
MEng programme). The numerical aspects of the project will also enable her to
apply biochemical engineering principles to the modelling of biological systems.
Bang Goes the Theory
Mike Hughson, an Research Engineer in the Industrial Doctoral Training Centre,
is also our resident ‘NOISEmaker’ (New Outlooks in Science & Engineering) for
the EPSRC. He was recruited last year as one of their ambassadors of science; he
received media and public engagement training and he’s passionate about getting
more people interested in science at A-level and university level.
He has been interviewed about vaccines by Phil Kennedy on Radio Berkshire’s
‘Drive Time’, done a live Q&A blog for The Guardian regarding careers in biological
research and, most recently, appeared as an extra on Bang Goes The Theory, a BBC 1
programme that was part of a citizen science campaign to get the general public
involved in taking measurements and sending them into whoever needs the data –
in this case, the Met Office.
5
© UCL Media Services, All Rights Reserved
Skilled Biochemical
Engineers
UCL Biochemical Engineering has just been re-awarded accreditation status for its
training of Undergraduate and Masters-level students of biochemical engineering.
This means that 80+ students graduating each year from the Department are eligible
to go on and gain Chartered Engineer status (CEng, MIChemE).
Why is this important now?
For the contract engineering sector of the bioprocessing industry this is the key
professional qualification for practising engineers. However, for all other parts of
the bioprocessing sector this is a crucial skill, and we are increasingly seeing our
graduates being required to take up Chartered Engineer status even when working
in research and development as well as in manufacture and design.
Chartered Engineer status confirms a skill basis and a rigorous understanding
of how best to translate new biological and life science discoveries into real process
outcomes. Success means not only cost-effective production of therapies and other
biological products but also robust processing which meets all the necessary safety and
regulatory validation standards and achieves product quality by design.
Why is this important for the future?
The need for safe, robust and economical processes designed and delivered by
biochemical engineers of the future are probably even more important for the
successful delivery of the next generation targets with which we are faced, such as
engineered proteins, stem cells, new vaccines and so-called cell factories, produced
as a result of synthetic biology. These and many other similar challenges are
central features of new aspects of biochemical engineering, sometimes described as
biological engineering.
How can you help?
The bioprocessing sector is one of most challenging of industries in which to turn
the promise of new discoveries into benefits for society. A wide range of high-level
skills are needed. One of the key skills is biochemical engineering.
There are literally thousands of UCL graduate biochemical engineers working in
your industries. The industrial experience they gain with you means they are qualified
to claim Chartered Engineer status. By doing so they gain important status in dealing
with professional bodies such as FDA, EMEA and HSE, as well as with colleagues in
the industry network required to deliver new products to society.
We are seeing an increasing number of companies in the bioprocessing sector
6
encouraging the uptake of chartered engineering status as an important career move.
When you next bump into one of our graduates why not ask them if they have gained chartered engineering status?
If they haven’t, tell them to get back in touch with us and we will provide the help and advice needed.
What’s in it for all of us?
The more we can raise the profile of professional biochemical engineers the more we will be able to create the
community and support to help meet the demand for skilled bioprocessing experts needed to deliver benefits of the
advances in the life, biomedical and biological sciences.
For more information about the benefits of chartered engineering please contact Prof. Mike Hoare at
m.hoare@ucl.ac.uk.
For information on how MBI® Bioprocessing delegates can eventually gain Chartered Engineer status please contact
Dr Karen Smith at k.smith@ucl.ac.uk.
7
Vision 2011 Senior
Leadership Course
VISION supporters
“Connectivity is our strength”
The VISION programme aims to be the nexus for the leaders of the biological
sciences industry to hear and debate the latest technological and business
developments in the sector.
Our second run of the Senior Leadership Course took place on 18–20 May in the
UCL Roberts Building Executive Suite. Thirteen senior industrial delegates spanning
the SME, mid-size enterprise and large pharma sectors were joined by representatives
from the National Skills Academy (Process Engineering) and the HealthTech and
Medicines KTN. They heard thought-provoking and sometimes controversial talks
from senior though-leaders drawn from across the bio-industries and they participated
in a range of stimulating case studies and moderated round table sessions.
Day 1
• Pathfinder Session Susan Dexter of Latham Biopharm
• Managing the next decade: Are you on track now? Dr Steve Arlington, PwC
• Networking Dinner
Day 2
• Business Case Studies: a Toolbox for Strategy Jonathon Marshall & Kate Moss, PwC
• Leadership: a Means to an End Rahul Singhvi, Novavax
• Can Biosimilars Innovate? Professor Barry Buckland, BiologicB
• Patenting: What to Avoid and What to Embrace Vicki Salmon, IP Asset LLP
• Round Table Discussion Moderator Martyn Postle, Asia Healthcare & Biotech Ltd
• Course Dinner; After-dinner talk – ‘How to Say No – and How to Know When
to Say No’ Dr Neil Weir, UCB
Day 3
• Supply Chain – How to Handle Uncertainty Ed Arcuri, Auxilium
• Biopharmaceutical Partnering: Due Diligence – Case Study Dr Michelle Scott,
Unicorn Biologics
Our next Vision event will be held on 15 September 2011 and is a Business Briefing
entitled Does QbD make business Sense? What new approaches to technology can make
it a viable proposition? Speaker: Richard Francis.
For further information please contact Dr Karen Smith at karen.smith@ucl.ac.uk
or Prof Eli Keshavarz-Moore at e.keshavarz-moore@ucl.ac.uk.
8
Prof. Eli Keshavarz-Moore with
Vicki Salmon and Michael Murray.
VISION delegates undertaking
a case study.
VISION delegates in the
Executive Suite.
9
Rahul Singhvi delivering his talk
‘Leadership: a means to an end’.
Prof Nigel Titchener-Hooker in
discussion with Susan Dexter (speaker)
and Vaughan Thomas (delegate).
Prof Steve Arlington delivering his
talk ‘Managing the next decade: are
you on track now?’.
10
EPSRC Centre for Innovative
Manufacturing in Emergent
Macromolecular Therapies
Creating manufacturing innovations so as to deliver affordable next generation
advanced therapies to the UK healthcare system
The UCL Department of Biochemical Engineering has been awarded £4.9m to establish an EPSRC Centre for
Innovative Manufacturing in Emergent Macromolecular Therapies, in collaboration with partners at Imperial College
and the London School of Pharmacy. Another £3.9m will be leveraged from industry over the life of the grant.
The EPSRC Centre will aim to deliver innovation in manufacturing research to assess emergent challenges facing
the UK biopharmaceutical sector, and which impact its global competitiveness. It will act as the focus for a national
network of leading users and academics in manufacturing and provide strong support for UK industry. It will become
recognised as the primary centre for the creation, delivery and dissemination of decision-support tools to enable
lifecycle optimisation of novel macromolecular therapies. This will widen access to valuable therapies for diseases such
as severe arthritis, cancers which are currently untreatable and multiple sclerosis by raising manufacturing efficiency
whilst reducing costs to the purchaser (e.g. NHS).
The current manufacturing model in the UK is rapidly becoming uncompetitive. While selection of the drug
lead for development is primarily based on clinical efficacy, significant advantage can be gained from early analysis
and development of the entire manufacturing pathway. Macromolecular medicines are complex products. They are
more costly to manufacture and use than conventional chemical medicines. If the fit of the manufacturing process
and design of the final medicine are poor, then costs will escalate and patient access will be restricted because of
acute budget pressures on the NHS. The UK global position in pharmaceutical development will also suffer, as
manufacturing practices will continue to migrate to regions where costs are low.
For more information about the Centre, please contact Prof. Nigel Titchener-Hooker at nigelth@ucl.ac.uk.
Project partners. Industry associations: ABPI, BIA, HealthTech & Medicines KTN. Companies: Aegis Analytical, Avacta, BioPharm
Services, BTG Plc, Eli Lilly, Francis BioPharma Consulting, GE Healthcare, GlaxoSmithKline, Lonza Biologics, MedImmune, Merck
& Co, MSD Biologics, Novo Nordisk, Novozymes Biopharma, Office of Health Economics (OHE), Pfizer, Syntaxin, The Automation
Partnership (TAP), UCB Pharma. Government-related: Health Protection Agency, NIBSC, NHS QIPP.
11
Responsive Bioprocessing Facility –
Planning for the Future
Single-use technologies (SUTs) are an
important addition to the bioprocess industry
and our ability to understand new designs,
evaluate their potential applications and
identify limitations will prove to be an
important aspect of their utilisation. Over
the past ten years the single-use market place
has become very crowded. New designs
and innovations have led to various formats
of bioreactors and downstream processes.
Currently there are over 60 companies
worldwide active in SUT processes and
analytics; these companies have created novel
designs and reinvented existing unit operations.
SUTs have several key advantages over
established stainless steel. Speed of production
and reduction in turnaround times can
increase productivity by 30%. Furthermore,
SUTs have the ability to rapidly expand in
order to meet seasonal demands because of
the flexible nature of their design and lower facilities requirements when compared to stainless steel.
But each new design requires engineering characterisation. Flow patterns, volume retentions, protein absorption
onto the material of construction, hydrodynamic shear and mixing times all determine the productivity of the step.
Additionally the choice of cell line, fusion protein product, virus or antibody could all have different binding and
interaction effects within the SUT unit.
As part of the re-fit of its primary research facility, the Advanced Centre for Biochemical Engineering, we have
recently created the Responsive Bioprocess Facility (RBF). This is a dedicated area committed to research, training
and knowledge transfer of single-use technologies. Already we are working with several companies to help populate
the area with new and interesting single-use units. Our desire is that this facility and the SUTs that it will contain
are embedded into some of our existing MBI courses. It will also serve as an opportunity to train our undergraduates
and Masters degree cohorts in the different operations, limitations and uses of SUTs when compared with traditional
stainless steel facilities.
With such a dedicated facility there will be opportunities for research into operations and cost-based analysis
of SUTs within existing PhD and EngD projects, but also for new projects. Depending on the level of company
engagement one option might be to recruit a dedicated PDRA (Post-Doctoral Research Associate) for short (threemonth) studies to produce a technical note, or perhaps longer (6–12 month projects) for an original publication. Our
hope is to attract the attention of the single-use community for such research opportunities so that the department and
its stakeholders can continue to meet the changing demands of the bioprocess industry.
For further information about the RBF, please contact Dr Tarit Mukhopadhyay at t.mukhopadhyay@ucl.ac.uk or
Dr Martina Micheletti at m.micheletti@ucl.ac.uk.
12
Bioprocess Briefings
Bioprocess Briefings are regular events for the bioprocessing community in which
seminars in recent bioprocessing research and development are given by high-profile
speakers. They are very popular with audiences of more than 100 commonplace.They
are followed by lively drinks receptions organised by the Beaker Society that provide
the audiences with excellent networking opportunities and the chance to talk with
speakers directly.
Bioprocess Briefings were designed as a component of the Innovative
Manufacturing Research Centre for Bioprocessing (IMRC) to facilitate knowledge
exchange. If an interested party is in or around the London area on a Briefing day,
they can make the most of their trip by attending. Since the briefings started in
January 2003 we have organised 63 Briefings.
The talks cover a wide range of topics from the manufacturing of advanced
therapeutics such as DNA vaccines, antibody, and antibody fragments to
fundamental understanding of cell properties and advanced analytical tools.
Our speakers are all international leaders in the bioprocessing field drawn
from the biopharma and biotech industries and academia. Previous speakers have
included Prof. Barry Buckland, ex-director of Bioprocessing R&D at Merck and
now CEO of Biologic B; Dr. Jonathan Coffman, Wyeth BioPharm (now Pfizer);
Prof. Conan J. Fee, Head of Department of Chemical Engineering, University
of Canterbury, New Zealand; Prof. M. Nazmul Karim, Chair of Chemical
Engineering, Texas Tech University; and Prof. Steve Cramer, Rensselaer Polytechnic
Institute, USA.
The recent May Briefing was given by Dr Debora Iglesias-Rodriguez from the
National Oceanography Centre, University of Southampton. She gave a fascinating
talk about microbial biomineralization and its applications in geoengineering and
carbon capture.
Dr Helen Mason from BP will talk about renewable biofuel research and
development on 28 July.
For more information about our Bioprocess Briefings please contact Dr Yuhong
Zhou at y.zhou@ucl.ac.uk.
13
SME Engagement: Immbio Case Study
ImmunoBiology Ltd (ImmBio) is a Cambridge-based SME company, working to develop novel
anti-infective vaccines addressing areas of high unmet need. The company’s pipeline is based
on two distinct technology platforms. The first, ImmBioVax™, replicates the innate stage of the
immune response to safely create protection and contains antigens, heat shock proteins and
antigenic proteins complexed to heat shock proteins. The second, ImmunoBodies™, consists of an antibody Fc-antigen
fusion protein approach. Both technology platforms target antigen delivery to the dendritic cells of the immune system,
which play a critical role in generating the immune responses necessary for successful protection against infectious
agents. Rapid development of cost-effective, viable production processes is critical for the success of a biotechnology
development organisation and particularly so for vaccine production. This need drove ImmBio’s initial collaboration
with the ACBE, a joint Technology-Strategy-Board-funded project (Manufacture of low cost, high-efficacy vaccines) with
Professor Mike Hoare. This project uses ACBE ultra scale-down (USD) approaches to predict process at scale for future
ImmunoBody vaccines. The collaboration provided ImmBio with an introduction to the broad range of ACBE courses
and collaborative opportunities open to Biotech Companies.
ImmBio’s management recognised the value of MBI® training modules to develop colleagues within the organisation.
ImmBio’s Head of Laboratory, Claire Entwisle, now uses the MBI® scheme to provide essential training not possible at
ImmBio. These training opportunities have to deliver real benefits to the organisation and must be cost-effective. This has
already proven to be the case for Dr Kate Dalton, a senior ImmBio scientist, who has attended several MBI® modules. We
then expanded our collaboration with the ACBE to include an EngD student, Eduardo Lau. This studentship strengthened
links between ImmBio and the ACBE, particularly for Dr Ann McIlgorm, a senior scientist at ImmBio, and has already
proved valuable as we develop new fusion protein production processes. The industry focus provided by the EngD training
programme and the quality of students recruited provided ImmBio with a colleague who rapidly made significant positive
impacts to the company. We have also taken an active role in the Industrial Training Advisory Board (ITAB), helping to
ensure that the training delivered to students closely matches the present and future needs of Companies such as ours.
The breadth of contacts and depth of experience available to a company through the industrial network established by
ACBE can prove invaluable. In one example, ImmBio identified an organisation, Novasep Process, and entered discussions
to provide GMP production through an initial contact made at a recent ITAB meeting. Benefits have not been limited
to technical developments; we have used the Vision programme to increase our knowledge of new business approaches
and to provide access to ‘in-job’ development on topics such as IP and Alliance management. Individual collaborations
and courses have proven to be beneficial to ImmBio and the presence of in house experts at the ACBE, such as Dr Tarit
Mukhopadhyay, has proved of value to our business. However, it is the synergy generated through the diverse range of
interactions and courses from TSB grant, EngD studentship, MBI® and Vision programmes that has proved to be most
valuable to us.
For further information about opportunities to collaborate with UCL and the range of training courses available,
please email Dr Karen Smith (karen.smith@ucl.ac.uk). For further information about ImmBio please contact Dr Shaun
McNulty, shaun.mcnulty@immbio.com, telephone: 01223 496122, or Graham Clarke (CEO), graham.clarke@immbio.
com, telephone 01223 496117.
If you would like further details about EngD opportunities, the MBI® or Vision programmes please contact Dr Karen
Smith at karen.smith@ucl.ac.uk in the first instance.
14
MBI® Module:
Principles of Fermentation
(3–5 October 2011)
‘Principles of Fermentation Processes’ will strengthen your knowledge of
fermentation processes, and through a series of lectures, case studies and a pilot
plant visit, will enable you to:
• Define different modes of fermentation and know their limitations.
• Develop a suitable medium and perform a material balance.
• Interpret fermentation data and use it effectively.
• Characterise the kinetics of cell growth and how they apply to different cell systems.
• Determine fermentation productivity and yields.
• Understand the impact of microbial physiology on fermentation performance.
• Develop a strategy for fermentation process development.
The module consists of lectures from industrial and academic experts, and interactive
problem-solving case studies performed in small groups for effective learning.
This module is suitable for scientists and engineers who wish to familiarise
themselves with fermentation processes and those who wish to build underlying
principles into their operational expertise in areas of research, process development
and manufacturing.
Monday 3 October
• Evaluation of different expression systems (Eli Keshavarz-Moore, UCL)
• Fermentation Mass Balancing (Gary Lye, UCL)
• Biomass Growth Kinetics (Frank Baganz, UCL)
• Tour of facilities
Tuesday 4 October
• Case Studies in Growth Kinetics (Frank Baganz, UCL), Mass Balancing
(Gary Lye, UCL) and Fermentation Simulation (Frank Baganz, UCL)
• New Developments in Fermentation Technology (Grainne McDonagh,
BioPharm Services Ltd)
• Different Modes of Fermentation Operation (Frank Baganz, UCL)
• Impact of Microbial Physiology on Fermentation (Colin Ratledge, Hull University)
Wednesday 5 October
• Case Study: Microbial Media Development (Gary Lye, UCL)
• Introduction to Animal Cell Culture (Farlan Veraitch, UCL)
• Present and Future Trends in Fermentation (James Mills, Cantabio)
A networking dinner will be held on the first evening. The module costs £1300.
Please contact mbi-training@ucl.ac.uk for further information.
15
The MBI Training
Programme is run by
the Department and
comprises a series of
UCL-accredited short
courses in bioprocessing,
designed specifically
for industrialists. They
can be taken as standalone modules or can be
combined for certificate,
diploma or Masters
qualifications. To date
1,000 modules have
been taught to over 700
international delegates, and
more than 200 companies
have participated.
Contacts
Research Sponsors and VISION:
Dr Karen Smith
Director of Bioprocess Leadership
+44 (0)20 7679 4411
karen.smith@ucl.ac.uk
MBI®:
Miss Liz Barrett
MBI® Manager
+44 (0)20 7679 1316
mbi-training@ucl.ac.uk
EPSRC Centre for Macromolecular
Therapies
Professor Nigel Titchener-Hooker
+44 (0)20 7679 3796
IMRC for Bioprocessing
Professor Mike Hoare
+44 (0)20 7679 3795
nigelth@ucl.ac.uk
BiCE, Engineering Doctorate in
Bioprocess Leadership and Industrial
Doctoral Training Centre for
Bioprocess Leadership (IDTC)
Professor Gary Lye
+44 (0)20 7679 7942
g.lye@ucl.ac.uk
RegenMed Bioprocessing
Professor Chris Mason
+44 (0)20 7679 0140
chris.mason@ucl.ac.uk
MBI® course dates 2011–12
Principles of Fermentation Processes: 3 – 5 October 2011
Rapid Fermentation Process Design: 17 – 19 October 2011
Challenges & Opportunities in Biocatalysis: 31 October – 2 November 2011
Primary Recovery: 14 – 17 November 2011
Chromatography: 28 November – 1 December 2011
Vaccines: 14 – 16 December 2011
Mammalian Cell Processes: 30 January – 1 February 2012
Stem Cell and Regenerative Medicine Bioprocessing: 20 – 22 February 2012
Quality by Design: 27 February – 1 March 2012
Design of Experiments for Bioprocess Optimisation: 12 – 14 March 2012
Effective Biopharmaceutical Development & Manufacture: 14 – 16 May 2012
Bioprocess Design & Economic Evaluation: 11 – 14 June 2012
Bioprocess Facility Design: 18 – 21 June 2012
For more information, email mbi-training@ucl.ac.uk
Work with us
The UCL Advanced Centre for Biochemical Engineering actively encourages and
fosters long-term research partnerships between its academics and sponsors for mutual
benefit. We facilitate interaction in a range of ways, such as sponsor visits, industrial
advisory boards, Bioprocess Briefings, industrial placements for graduate students
and the MBI® Programme. Over 70 industrial and academic experts contribute to our
MBI® activities. If you would like further information, please contact the appropriate
member of staff listed to the left.
16